(Q44248035)

1 December 2017

title

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis (English)

1 reference

1 December 2017

0 references

Pamela L Zeitlin

17

0 references

author name string

Ronald L Gibson

1

1 reference

1 December 2017

Julia Emerson

2

1 reference

1 December 2017

Sharon McNamara

3

1 reference

1 December 2017

Jane L Burns

4

1 reference

1 December 2017

Margaret Rosenfeld

5

1 reference

1 December 2017

Ann Yunker

6

1 reference

1 December 2017

Nicole Hamblett

7

1 reference

1 December 2017

Frank Accurso

8

1 reference

1 December 2017

Mark Dovey

9

1 reference

1 December 2017

Peter Hiatt

10

1 reference

1 December 2017

Michael W Konstan

11

1 reference

1 December 2017

Richard Moss

12

1 reference

1 December 2017

George Retsch-Bogart

13

1 reference

1 December 2017

Jeffrey Wagener

14

1 reference

1 December 2017

David Waltz

15

1 reference

1 December 2017

Robert Wilmott

16

1 reference

1 December 2017

Bonnie Ramsey

18

1 reference

1 December 2017

Cystic Fibrosis Therapeutics Development Network Study Group

19

1 reference

1 December 2017

language of work or name

English

0 references

publication date

12 December 2002

1 reference

American Journal of Respiratory and Critical Care Medicine

1 December 2017

published in

1 reference

1 December 2017

volume

167

1 reference

1 December 2017

issue

6

1 reference

1 December 2017

page(s)

841-849

1 reference

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Bacterial biofilms: a common cause of persistent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Lower airway inflammation in infants and young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Predictive Value of Oropharyngeal Cultures for Identifying Lower Airway Bacteria in Cystic Fibrosis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Microbiology of sputum from patients at cystic fibrosis centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

A Multiple Testing Procedure for Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Regional variability of lung inflammation in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Adult-type pulmonary function tests in infants without respiratory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Micro-determination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Susceptibility of bacterial biofilms to tobramycin: role of specific growth rate and phase in the division cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200208-855OC

10.1164/RCCM.200208-855OC

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference